Development of CRISPR technology and its application in bone and cartilage tissue engineering.
10.12122/j.issn.1673-4254.2019.12.19
- Author:
Guo CHEN
1
;
Du CHENG
2
;
Bin CHEN
1
Author Information
1. Department of Traumatology and Orthopedics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
2. School of Material Science and Engineering, Sun Yat-sen University, Guangzhou 510275, China.
- Publication Type:Journal Article
- Keywords:
CRISPR;
bone engineering;
cartilage tissue engineering;
genome editing
- MeSH:
CRISPR-Cas Systems;
Cartilage;
Clustered Regularly Interspaced Short Palindromic Repeats;
RNA, Guide;
Tissue Engineering
- From:
Journal of Southern Medical University
2019;39(12):1515-1520
- CountryChina
- Language:Chinese
-
Abstract:
The CRISPR/Cas9 system, consisting of Cas9 nuclease and single guide RNA (sgRNA), is an emerging gene editing technology that can perform gene reprogramming operations such as deletion, insertion, and point mutation on DNA sequences targeted by sgRNA. In addition, CRISPR/dCas9 (a mutant that loses Cas9 nuclease activity) still retains the ability of sgRNA to target DNA. The fusion of dCas9 protein with transcriptional activator (CRISPRa) can activate the expression of the target gene, and fusion transcriptional repressors (CRISPRi) can also be used to suppress target gene expression. Efficient delivery of the CRISPR/Cas9 system is one of the main problems limiting its wide clinical application. Viral vectors are widely used to efficiently deliver CRISPR/Cas9 elements, but non-viral vector research is more attractive in terms of safety, simplicity, and flexibility. In this review, we summarize the principles and research advances of CRISPR technology, including CRISPR/ Cas9 delivery vectors, delivery methods, and obstacles to the delivery, and review the progress of CRISPR-based research in bone and cartilage tissue engineering. Finally, the challenges and future applications of CRISPR technology in bone and cartilage tissue engineering are discussed.
